DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 2 Jim Cramer - 2 Humana - 2 Susan Diamond - 2 Bruce Broussard - 2 Broussard - 2 Jim Cramer's - 2 Jim - 2
Top related locs:
Louisville , Kentucky
Top related orgs:
Revenue - 2 Humana - 2 UnitedHealth - 2 CNBC - 2 Medicare - 1 Inc - 1 Club - 1 Management - 1

Search resuls for: "MLR —"


5 mentions found


☆ The sell-off in Humana is overdone after strong earnings. Jim Cramer says buy the stock
  + stars: | 2023-11-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +7 min
"The story is on track, and I think you buy the stock," Jim Cramer said during Wednesday's Morning Meeting . Since its 2023 lows on July 13, Humana stock rallied more than 23% compared with a roughly 7% slide in the S & P 500 over the same stretch. Management's initial commentary on 2024 earnings and Medicare Advantage membership growth — discussed in more detail below — may also have left investors wanting. Humana also expects EPS growth in 2024 to fall on the lower end of its historical long-range 11%-to-15% target. Capital allocation Humana still expects to buy back about $1.5 billion worth of stock in 2023, finance chief Diamond said on the earnings call.
Persons: —, Jim Cramer, they've, UnitedHealth, Humana, Susan Diamond, Diamond, Bruce Broussard, Jim Rechtin, Broussard, Jim Cramer's, Jim Organizations: Medicare, Revenue, Humana, UnitedHealth, CNBC, Inc
☆ Humana calms Wall Street's jitters with quarterly results, clearing way for stock to run higher
  + stars: | 2023-08-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +5 min
Humana (HUM) reported second-quarter results Wednesday that were much better than feared, sending its stock price soaring and giving us the confidence to stick with the jilted health insurer. Not only did second-quarter numbers top expectations, but management offered assuring commentary on the worrisome medical-cost trends that torpedoed its stock price in mid-June . That one-two punch explains the more-than-5% jump in Humana shares, pushing the stock to its highest levels since June 14. Outlook Humana raised its outlook for 2023 individual Medicare Advantage membership growth by 50,000 to roughly 825,000 members, representing an 18% increase compared with enrollment levels at the end of 2022. Capital allocation Humana CFO Susan Diamond said the company has capitalized on the "recent dislocation" in its stock price — i.e.
Persons: MLR —, Wall, Bruce Broussard, —, Broussard, Susan Diamond, Humana, Jim Cramer's, Jim Cramer, Jim, Ty Wright Organizations: Revenue, Humana, Club, UnitedHealth, Management, Insurance, CNBC, Bloomberg, Getty Locations: Louisville , Kentucky
☆ Humana's outlook brightens, positioning the health insurer for a year of upside
  + stars: | 2023-04-26 | by ( Zev Fima | ) www.cnbc.com   time to read: +5 min
Adjusted revenue increased 12% year-over-year, to $25.65 billion, slightly below analysts' forecasts of $26.44 billion, according to estimates compiled by Refinitiv. Looking forward, we expect the strong membership-growth rates seen in the first quarter to drive further upside throughout 2023. The 2023 benefits expense ratio range was left unchanged, in a range of 86.3% to 87.3%, slightly above the 86.6% ratio predicted by analysts at the midpoint. Full-year operating cash flow guidance was also left unchanged, at $4.5 billion, compared with analysts' forecasts for $4.36 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
☆ Humana is set to soar in 2023 after delivering strong Q4
  + stars: | 2023-02-01 | by ( Zev Fima | ) www.cnbc.com   time to read: +7 min
Health insurer Humana (HUM) on Wednesday reported a stellar fourth quarter and provided a robust full-year outlook, setting the Club holding up for significant growth in 2023. Outlook Management guided for full year 2023 adjusted earnings-per-share to be at least $28, in line with analysts' forecasts. The 2023 benefits expense ratio range of 86.3% to 87.3% is slightly above the 86.3% ratio predicted by analysts, at the midpoint. But given the company already expects to be above the industry growth rate in 2023, Humana is ahead of expectations — bolstering the Club's confidence in the achievability its long-term outlook. But Humana's management only said they're still "reviewing the final rule and considering its impact."
☆ We're impressed with health insurer Humana's solid quarter and rosy outlook for next year
  + stars: | 2022-11-02 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
Full-year 2022 guidance was in-line with the updated outlook provided at the health insurer's September investor day. But we did get some commentary looking ahead to 2023 that pushed the stock 2% higher in Wednesday's down market. The Q3 benefits expense ratio in the quarter was 86.5%, down (again, lower is better), down from 88.1% in the year ago period. The Q3 benefits expense ratio in the quarter saw significant improvement, falling to 78.7% from 86.4% last year. Outlook Management affirmed their adjusted full-year 2022 EPS outlook of approximately $25 per share, representing 21% annual growth versus 2021 an in-line with expectations.
0 next >>
Total: 5